Prof. Gavin Halbert

Prof. Gavin Halbert
Cancer Research UK
Formulation Unit,
Strathclyde Institute of Pharmacy
and Biomedical Sciences,
University of Strathclyde
g.w.halbert@strath.ac.uk

Gavin Halbert is a Pharmacy graduate from the University of Strathclyde in 1979, pre-registration in industrial and hospital pharmacy settings followed by a PhD in Physiochemical Aspects of Anti-Cancer Drug Targeting Systems in 1984. Qualified Person under the provision of EC Directive 2001/20 and Member of the Royal Society of Chemistry. Appointed as a lecturer in 1984 to the Department of Pharmaceutics at the University of Strathclyde and then Director of the Formulation Unit in 1992. The Unit's role is to characterise, analyse, formulate and manufacture putative anti-cancer drugs accepted by CRUK's New Agents Committee for use in human clinical trials. Pharmaceutically responsible for over 20 novel NCE's for Phase I trial including temozolomide, abiraterone acetate, vadimezan and others. Career grant income of over £20 million and over 150 published papers, conference abstracts and presentations.

Research Interests

Research interests, include medicinal and analytical chemistry, drug physiochemistry, formulation for both small volume and parenteral and oral products and the GMP production of specialist pharmaceutical products clinical trials. The latter incorporates research areas such as microbiology and lyophilisation. In addition related research is conducted in drug targeting and delivery systems for cancer chemotherapy for example synthetic Low Density Lipoprotein systems.

Representative Publications

Schmidt, E., Dooley, N., Ford, S.J., Elliott, M., Halbert, G.W., 2012. Physicochemical investigation of the influence of saccharide-based parenteral formulation excipients on l-p-boronphenylalanine solubilisation for boron neutron capture therapy. Journal of Pharmaceutical Sciences 101, 223-232.

Elliott, M.A., Ford, S.J., Prasad, E., Dick, L.J., Farmer, H., Hogg, P.J., Halbert, G.W., 2012. Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial. International Journal of Pharmaceutics 426, 67-75.

Schmidt, E., Dooley, N., Ford, S.J., Elliott, M., Halbert, G.W., 2011. Physicochemical investigation of the influence of saccharide-based parenteral formulation excipients on l-p-boronphenylalanine solubilisation for boron neutron capture therapy. Journal of Pharmaceutical Sciences 101, 223-232.

Danson, S.J., Johnson, P., Ward, T.H., Dawson, M., Denneny, O., Dickinson, G., Aarons, L., Watson, A., Jowle, D., Cummings, J., Robson, L., Halbert, G., Dive, C., Ranson, M., 2011. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Annals of Oncology 22, 1653-1660.

Dick, L., Dooley, N., Elliott, M.A., Ford, S.J., Gordon, M.R., Halbert, G.W., Kerr, W.J., 2011. Boron phenylalanine and related impurities: HPLC analysis, stability profile and degradation pathways. Journal of Pharmaceutical and Biomedical Analysis 56, 633-636.

Schmidt, E., Dooley, N., Ford, S., Elliot, M., Halbert, G., 2010. Effects of substituting Fructose by Mannitol in a pharmaceutical formulation. Journal of Pharmacy and Pharmacology 62, 1428-1429.

Zhou, P., Hatziieremia, S., Elliott, M.A., Scobie, L., Crossan, C., Michie, A.M., Holyoake, T.L., Halbert, G.W., Jorgensen, H.G., 2010. Uptake of synthetic Low Density Lipoprotein by leukemic stem cells - a potential stem cell targeted drug delivery strategy. J Control Release 148, 380-387.

Lee, C.P., Payne, G.S., Oregioni, A., Ruddle, R., Tan, S., Raynaud, F.I., Eaton, D., Campbell, M.J., Cross, K., Halbert, G., Tracy, M., McNamara, J., Seddon, B., Leach, M.O., Workman, P., Judson, I., 2009. A phase I study of the nitroimidazole hypoxia marker SR4554 using F-19 magnetic resonance spectroscopy. British Journal of Cancer 101, 1860-1868.